Related Experiment Video
Updated: Aug 11, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
T lymphocytes as potential therapeutic drug carrier for cancer treatment
Ute Steinfeld1, Christine Pauli, Nikolas Kaltz
1Korea Institute of Science and Technology Europe, Universität des Saarlandes, Stuhlsatzenhausweg 97, D-66123 Saarbrücken, Germany. steinfeld@kist-europe.de
The aim of our research is the application of human immune cells (T lymphocytes) as target directed drug carrier. Thereby, the inclusion of therapeutical nanoparticles into immune cells is a new strategy for a localized chemotherapy. The autonomous targeting of diseased sites makes immune cells to perfectly controlled drug delivery systems. The study's aim was to demonstrate the feasibility to mobilise immune cells as therapeutic drug carrier systems which can be combined with existing immunotherapies. Therefore, Jurkat cells as well as T lymphocytes were used to identify the smoothest procedure for loading nanoparticles into immune cells. Different loading processes, incubation times and nanoparticle concentrations were compared. Nanoparticles coated with cytotoxic antibiotic doxorubicin were used in first release experiments. A time dependent liberation of doxorubicin from carrier cells was discussed as first therapeutic approach.
The aim of our research is the application of human immune cells (T lymphocytes) as target directed drug carrier. Thereby, the inclusion of therapeutical nanoparticles into immune cells is a new strategy for a localized chemotherapy. The autonomous targeting of diseased sites makes immune cells to perfectly controlled drug delivery systems. The study's aim was to demonstrate the feasibility to mobilise immune cells as therapeutic drug carrier systems which can be combined with existing immunotherapies. Therefore, Jurkat cells as well as T lymphocytes were used to identify the smoothest procedure for loading nanoparticles into immune cells. Different loading processes, incubation times and nanoparticle concentrations were compared. Nanoparticles coated with cytotoxic antibiotic doxorubicin were used in first release experiments. A time dependent liberation of doxorubicin from carrier cells was discussed as first therapeutic approach.
